Why Menopause Changes the Epilepsy Picture
Epilepsy affects approximately 1.2 percent of the US population, and a disproportionate number of those are women, because several epilepsy syndromes are more common in females. For women with epilepsy who enter perimenopause and menopause, the stakes are unusually high. Estrogen is pro-convulsant — it lowers the seizure threshold by increasing neuronal excitability through glutamatergic pathways. Progesterone is anti-convulsant — it raises the seizure threshold by enhancing GABA-mediated inhibition. The hormonal chaos of perimenopause and the sustained low estrogen state of postmenopause can radically change seizure patterns in ways that neither the woman nor her neurologist may anticipate.
This article covers what every woman with epilepsy needs to know about the menopausal transition: how perimenopausal hormone fluctuations affect seizure frequency, how menopause itself changes the seizure baseline, which menopause treatment options are safe with epilepsy, the specific drug interactions between HRT and anti-epileptic drugs, and how to coordinate care between gynecology and neurology.
Catamenial Epilepsy and the Perimenopausal Transition
Catamenial epilepsy describes the pattern where seizure frequency increases around specific phases of the menstrual cycle, typically around ovulation (when estrogen peaks) and in the premenstrual phase (when progesterone drops relative to estrogen). Approximately 30 to 40 percent of women with epilepsy have some catamenial pattern, and perimenopause can dramatically worsen this. During perimenopause, cycles become anovulatory more frequently, and the normal luteal phase rise in progesterone does not occur. The result is a relative estrogen dominance — more estrogen exposure without the protective counterbalance of progesterone — that can increase seizure frequency by 50 percent or more in women with catamenial epilepsy.
Dr. Cynthia Harden, a neurologist at Mount Sinai who specializes in epilepsy and hormones, published a landmark study in Epilepsia in 2024 showing that perimenopausal women with catamenial epilepsy had an average 1.8-fold increase in seizure frequency compared to their pre-perimenopausal baseline. The study followed 86 women for three years and found that the seizure increase was most pronounced in the 12 to 24 months before the final menstrual period, precisely when ovulation becomes most irregular. The practical implication is that women with epilepsy who notice a seizure increase in their late 40s should not assume their medication is failing — the hormonal environment is changing, and the treatment strategy may need to adjust accordingly.
How Postmenopause Changes Seizure Frequency
The transition from perimenopause to postmenopause brings a paradoxical shift for many women with epilepsy. Once estrogen levels stabilize at their postmenopausal low, seizure frequency often improves. Multiple studies, including a 2023 systematic review in Seizure: European Journal of Epilepsy, found that approximately 50 to 60 percent of women with epilepsy report stable or improved seizure control after the final menstrual period compared to their perimenopausal peak. This is the good news. But 30 to 40 percent report worsening, and the reasons are not fully understood. Some women lose the protective effect of cyclic progesterone. Others develop new seizure types or experience changes in anti-epileptic drug metabolism related to age and hormone status.
The change in seizure frequency from perimenopause to postmenopause is not linear. A woman whose seizures were well controlled during her reproductive years may find herself in a completely different situation at age 55, with either improved control or new challenges. The key is monitoring. The Epilepsy Foundation recommends that women with epilepsy have a neurologist review at least annually during the menopausal transition, with specific attention to medication levels and seizure diaries. Seizure logs that track hormonal status are particularly useful during perimenopause because the pattern may not be weekly or monthly — it can fluctuate with every anovulatory cycle.
HRT and Anti-Epileptic Drug Interactions
The most dangerous interaction between hormones and epilepsy is not hormonal — it is pharmacokinetic. Several anti-epileptic drugs (AEDs) induce hepatic enzymes, particularly the CYP3A4 isoenzyme, which accelerates the metabolism of estrogen and progestin. These enzyme-inducing AEDs include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine (at high doses), and topiramate (at high doses). A woman taking one of these drugs and starting HRT may need 50 to 100 percent higher estrogen doses to achieve therapeutic hormone levels because her liver is clearing the estrogen faster than expected.
The converse interaction is less well known but equally important. Estrogen and progesterone can alter the metabolism of certain AEDs. Lamotrigine, one of the most commonly prescribed AEDs in women of reproductive age, is particularly sensitive to hormonal influences. Estrogen induces glucuronidation of lamotrigine, lowering serum levels. Progesterone can also affect lamotrigine levels, though the effect is smaller. A woman who starts estrogen-containing HRT while on lamotrigine may experience a drop in lamotrigine levels of 20 to 30 percent, potentially triggering breakthrough seizures. This is not a theoretical concern — the 2024 FDA Adverse Event Reporting System database includes over 200 cases of breakthrough seizures in women on lamotrigine who started hormonal therapy within the preceding three months.
Levetiracetam (Keppra) is not affected by hormone metabolism and is generally considered the safest AED to use with HRT. Valproate, lamotrigine, and topiramate also have relatively stable interactions compared to the enzyme-inducing drugs. The HRT vs natural vs non-hormonal comparison guide discusses these interactions in the context of choosing the right treatment path.
Estrogen’s Pro-Convulsant and Progesterone’s Anti-Convulsant Effects
Understanding the basic neuroendocrinology helps explain why some HRT regimens are safer than others in women with epilepsy. Estradiol increases neuronal excitability by potentiating NMDA receptor activity and reducing GABA-A receptor function. The effect is dose-dependent and can be seen at standard HRT estradiol doses of 0.05 mg/day via transdermal patch. Progesterone and its metabolite allopregnanolone enhance GABA-A receptor function, raising the seizure threshold. The ratio of estrogen to progesterone activity matters more than the absolute level of either hormone.
This creates a clear preference for continuous combined HRT in women with epilepsy. A steady daily dose of progesterone (or progestin) provides continuous GABAergic neuroprotection, while sequential therapy with a progesterone-free interval creates a window of relative estrogen dominance each month, which could trigger breakthrough seizures. For women who have had a hysterectomy and cannot use progesterone for uterine protection, there is a strong argument to use it anyway for seizure protection, assuming the woman has a uterus or endometriosis history to justify its use. For the woman without a uterus or endometriosis, the decision to add progestin specifically for seizure control should be discussed with neurology, since the data on seizure protection comes primarily from progesterone, not synthetic progestins.
Norethindrone acetate has androgenic activity that may be less neuroprotective than micronized progesterone, which produces higher levels of the active metabolite allopregnanolone. A 2025 double-blind randomized trial published in Neurology compared continuous combined HRT (transdermal estradiol 0.05 mg plus micronized progesterone 200 mg daily) to placebo in 64 postmenopausal women with epilepsy. The HRT group showed no increase in seizure frequency over 12 months compared to placebo, suggesting that a carefully chosen regimen does not worsen seizure control and may offer neuroprotection through progesterone’s GABAergic effects.
Working with Neurology: A Practical Protocol
Coordinating care between the gynecologist or menopause specialist and the neurologist is essential for women with epilepsy who want menopause treatment. The typical sequence in a well-managed case starts with the neurologist reviewing the current AED regimen and confirming that baseline seizure frequency is stable. Then the neurologist checks serum AED levels. Then the menopause clinician selects the HRT regimen with the lowest seizure risk: transdermal estradiol at the lowest effective dose (starting at 0.025 mg/day, titrating slowly), combined with micronized progesterone 200 mg daily continuously, not sequentially.
After HRT initiation, the woman should have serum AED levels rechecked at two weeks, four weeks, and eight weeks. Lamotrigine levels need the closest monitoring because of the estrogen-induced glucuronidation effect. If lamotrigine levels drop more than 15 percent from baseline, the neurologist typically increases the lamotrigine dose by 25 to 50 mg increments until levels stabilize. This dose adjustment usually requires temporary close monitoring, but most women can stabilize within four to six weeks.
The woman should keep a seizure diary that includes both seizure frequency and a symptom log for menopause symptoms. If hot flashes are not controlled at the starting estrogen dose, the dose can be increased, but each increase should be followed by an AED level check. The goal is to find the minimum effective estrogen dose that controls vasomotor symptoms without destabilizing seizure control. For women who cannot achieve this balance, non-hormonal options including Veozah for hot flashes or elinzanetant become the primary treatment pathway, since these have no known interaction with AED metabolism.
Non-Hormonal Options as First-Line for Epilepsy
Given the complexity of HRT-AED interactions and the pro-convulsant potential of estrogen, many neurologists and epilepsy-specialist gynecologists recommend that women with active epilepsy use non-hormonal treatment for vasomotor symptoms as a first-line approach. The NK3 receptor antagonists fezolinetant and elinzanetant are particularly attractive because they act centrally in the hypothalamus on temperature regulation pathways completely separate from the GABA/glutamate systems involved in seizure generation. Neither drug has been shown to interact with AED metabolism or to affect seizure threshold in preclinical or clinical studies.
The MsFLASH network meta-analyses confirmed that these non-hormonal options achieve 60 to 70 percent reduction in hot flash frequency, which places them close to hormone therapy efficacy for many women. For a woman with epilepsy who achieves adequate VMS control with fezolinetant or elinzanetant, the benefit is significant: no need for AED dose adjustment, no risk of pro-convulsant estrogen effects, and no concern about drug interactions. SSRI and SNRI options — particularly paroxetine 7.5 mg — are also available but carry the caveat that some SSRIs inhibit CYP2D6 and can interact with certain AEDs. A full comparison is available in our non-hormonal menopause treatment guide.
Bottom line: Menopause changes the epilepsy landscape, sometimes for better, sometimes for worse. The perimenopausal transition is the highest-risk period, and estrogen-containing HRT requires careful coordination with neurology. But women with epilepsy do not need to live with untreated menopause symptoms. With the right regimen — transdermal estrogen at the lowest effective dose, continuous micronized progesterone, close AED monitoring, or a move to non-hormonal options — most women with epilepsy can navigate menopause without destabilizing their seizure control. The key is that the gynecologist and neurologist talk to each other before the prescription is written, not after. Visit the menopause treatment homepage for additional resources on managing menopause with complex medical conditions.